is rapamycin a peptide peptide - RapamycinmTORC2 Rapamycin is a specific mTOR inhibitor Is Rapamycin a Peptide? Understanding the Nature of This Potent Compound

Rapamycin(mTOR) The question of is rapamycin a peptide is a common one, particularly as research delves deeper into its multifaceted biological activities.作者：S Singh·2021·被引用次数：2—Recent efforts have been made to synthesize rapamycin peptide conjugates in whichrapamycin is conjugated to peptideswhich are known for their ... While rapamycin shares some characteristics with biological molecules, its classification is distinctRapamycin (Sirolimus) | mTOR Inhibitor | CAS 53123-88-9. Rapamycin, also known as sirolimus, is primarily recognized as a macrolide antibiotic. This classification stems from its complex macrocyclic structure, which is a hallmark of macrolides. It was originally isolated from the soil bacterium *Streptomyces hygroscopicus* found on Easter Island.

Despite not being a peptide, rapamycin plays a significant role in cellular processes often associated with peptide signaling and regulation. Its primary mechanism of action involves the inhibition of the mammalian target of rapamycin (mTOR), a crucial serine-threonine protein kinase. This kinase acts as a central regulator of cell growth, metabolism, catabolism, immune responses, and autophagy.Rapamycinis a protein kinase inhibitorthat is used for immunosuppression in transplant patients and is under investigation as a cancer treatment. Rapamycin ... By binding to FKBP12, rapamycin forms a complex that allosterically inhibits mTOR, particularly mTORC1. This inhibition has led to rapamycin being investigated for a wide range of applications, from its established use as an immunosuppressant in organ transplant patients to its potential in anti-aging therapies and as an anticancer agent.

The intricate relationship between rapamycin and cellular signaling pathways has led to its exploration in conjunction with peptides. Research has investigated the synthesis of rapamycin-peptide conjugates. In these studies, rapamycin is also conjugated to the peptides that are known for their specific biological activities, such as inhibiting the kinase activity of the Akt protein.Rapamycin (Sirolimus) | mTOR Inhibitor | CAS 53123-88-9 These conjugates are designed to act as dual-target agents, leveraging the strengths of both rapamycin and the attached peptides to achieve enhanced therapeutic effects. For instance, rapamycin is conjugated to peptides to create novel delivery systems, such as biomimetic peptide nanoparticles, which can facilitate the targeted delivery of rapamycin. Furthermore, peptide-like compounds have been shown to generate synergistic antifungal effects when used in combination with rapamycin, demonstrating another facet of their intricate interaction.

It is important to clarify that while rapamycin interacts with FKBP12, which is a protein, and can be conjugated to peptides, rapamycin itself is not a peptide. Peptides are typically short chains of amino acids, whereas rapamycin's structure is a macrolide.作者：A Wang·2024·被引用次数：3—Results show that the main amino acid residues on the mammalian target of rapamycin that bind to RAPA are constructed as peptides (P1 and P2), which have ... However, the concept of a Target of Rapamycin peptide exists, which is applicable as a control peptide for blocking antibody binding in Western blotting, further highlighting the nuanced terminology surrounding this compound. The rapamycin-binding domain of mTOR is also a subject of study, and Protein Kinase Inhibitor Peptide (PKI) is a related concept in the field of kinase inhibition.

The broad therapeutic potential of rapamycin is continuously being uncovered. Its ability to modulate fundamental cellular processes makes it a subject of intense scientific inquiry. While its roots are in immunosuppression and transplant medicine, the investigation into its role in longevity and the postponement of aging-related processes is a significant area of ongoing research. The drug's efficacy as an antifungal agent is also noted, alongside its potent antitumor and immunosuppressive activity. The recent attention rapamycin has garnered in discussions about longevity, sometimes drawing parallels to other popular compounds like GLP-1 for longevity, underscores its growing significance in biomedical research.

In summary, while rapamycin is a macrolide antibiotic and not a peptide, its profound impact on cellular signaling, particularly through its inhibition of mTOR, has led to extensive research exploring its conjugation with and interaction with peptides for various therapeutic applications. The complex nature of rapamycin and its interactions continues to be a fertile ground for scientific discovery.